You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

23 search results for: barrier dysfunction

Skin <b>Barrier</b>, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

69 min

Dermatology

Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.

Skin <b>Barrier</b>, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

11 min

Dermatology

Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.

Role of Type 2 Inflammation in Skin <b>Barrier</b> Disruption and Itch

expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

4 min

Dermatology

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD

expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

15 min

Dermatology

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

expert video

Diving Below the Surface of AD: The Role of Type 2 Inflammation

10 min

Dermatology

This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.

videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min

Dermatology

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

expert video

Type 2 Inflammation Within Skin Tissue in AD

4 min

Dermatology

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

2 min

Dermatology

Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.

expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

18 min

Dermatology

The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

2 min

Dermatology

Discover the pathophysiological mechanisms involved in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region